Antibe Therapeutics Inc.
ATE
Rank in Stocks
#31923
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Share Price
$0.21483059
Last synced: 2024-05-07
Market Cap
$11.13M
Change (1 day)
0.34%
Change (1 year)
-0.36%
Country
CA
Trade Antibe Therapeutics Inc. (ATE)
Category
Healthcare
EPS for Antibe Therapeutics Inc. (ATE)
EPS as of 2026 TTM: 0
According to Antibe Therapeutics Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Antibe Therapeutics Inc. from 2026 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $3.11 | - |
US
|
|
| $3.59 | - |
IE
|
|
| $9.73 | - |
US
|
|
| $2.48 | - |
US
|
|
| - | - |
DE
|
